JAZZ Maintains Overweight Rating -- Price Target Lowered to $314

gurufocus.com · 2026-10-21

Jazz Pharmaceuticals: Analyst Rating Update and Valuation Insights On October 10, 2023, Jazz Pharmaceuticals (JAZZ) received an Overweight rating from Morgan

TickrTrends take: Jazz Pharmaceuticals maintains an overweight rating from analysts despite a price target reduction to 314, suggesting the market still views the company as having upside potential despite recent valuation adjustments. Given TickrTrends' assessment that JAZZ is fairly valued, the lowered price target indicates analyst expectations may have shifted on growth or earnings assumptions rather than a fundamental revaluation of the company's standing. Investors focused on valuation metrics should monitor whether this rating change reflects sector-wide Healthcare pressures or company-specific factors that could affect fair value assessments going forward.

Read the full story at gurufocus.com →